Sugi Predict

Sugi Predict / Compounds / SCHEMBL1980701

SCHEMBL1980701

SCHEMBL1980701

COc1ccc(C)c(Oc2ccc(N)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ TDP1 Q9NUW8 4/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ ALDH1A1 P00352 9/20 0.52
▸ CYP3A4 P08684 4/20 0.52
▸ CYP19A1 P11511 3/20 0.49
▸ TEAD4 Q15561 1/20 0.48
▸ MAPT P10636 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ TSHR P16473 1/20 0.46
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ THRB P10828 1/20 0.44
▸ NR4A1 P22736 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20854262 0.89 ALDH1A1 (0.59) SMN1; SMN2TDP1MAPK1ALDH1A1CYP3A4
SCHEMBL1979667 0.85 SMN1; SMN2 (0.58) SMN1; SMN2TDP1MAPK1ALDH1A1CYP3A4
SCHEMBL17354635 0.85 ACHE (0.54) SMN1; SMN2TDP1MAPK1ALDH1A1CYP3A4
SCHEMBL7038743 0.83 LTA4H (0.57) SMN1; SMN2MAPK1ALDH1A1POLBCA12
SCHEMBL30626927 0.82 ALDH1A1 (0.69) SMN1; SMN2TDP1MAPK1ALDH1A1CYP3A4
SCHEMBL1271060 0.82 ALDH1A1 (0.69) SMN1; SMN2TDP1MAPK1ALDH1A1CYP3A4
SCHEMBL22829560 0.79 TEAD4 (0.61) SMN1; SMN2TDP1ALDH1A1CYP3A4TEAD4
SCHEMBL1982560 0.79 KDM4E (0.62) SMN1; SMN2TDP1MAPK1ALDH1A1CYP3A4
SCHEMBL5549511 0.78 TDP1 (0.54) SMN1; SMN2TDP1MAPK1ALDH1A1CYP3A4
SCHEMBL29837419 0.78 CA12 (0.65) ALDH1A1CYP3A4MAPTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2852589-B1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2021-04-28 — — EP disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-10160730-B2 Triazoles as KV3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2018-12-25 — — US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 — — US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 — — US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 — — US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 — — US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885TDP1 2396/4885MAPK1 808/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885TDP1 2396/4885MAPK1 808/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885TDP1 2396/4885MAPK1 808/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885TDP1 2396/4885MAPK1 808/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885TDP1 2396/4885MAPK1 808/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2949/4885TDP1 3019/4885MAPK1 1000/4885
US-10160730-B2 Triazoles as KV3 inhibitors KCNA3, KCNN3, KCNK3 SMN1; SMN2 3663/4885TDP1 2296/4885MAPK1 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.